The STAT3 inhibitor stattic impairs cardiomyocyte mitochondrial function through increased reactive oxygen species formation

Current Pharmaceutical Design

Volumn 19, Issue 39, 2013, Pages 6890-6895

  Boengler, Kerstin ^a   Ungefug, Elvira ^a   Heusch, Gerd ^b   Schulz, Rainer ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

ATP; Heart; Mitochondria; STAT; Transition pore

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ACETYLCYSTEINE; ADENOSINE TRIPHOSPHATE; AMPLEX ULTRARED; ANTIMYCIN A1; CALCIUM; CALCIUM CHLORIDE; DIMETHYL SULFOXIDE; DYE; GLUTAMIC ACID; HYDROGEN PEROXIDE; MALIC ACID; PROTEIN INHIBITOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; STAT3 PROTEIN; STATTIC; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL FUNCTION; CELL ISOLATION; CONTROLLED STUDY; ENZYME SUBSTRATE; FLUORESCENCE IMAGING; HEART LEFT VENTRICLE; HEART MITOCHONDRION; HEART MUSCLE CELL; MEDIATOR; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADENOSINE TRIPHOSPHATE; ANIMALS; CYCLIC S-OXIDES; MITOCHONDRIA, HEART; MYOCYTES, CARDIAC; PHOSPHORYLATION; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; STAT3 TRANSCRIPTION FACTOR;

EID: 84883769811     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161281939131127115940     Document Type: Article

References (57)

1. Boengler K, Hilfiker-Kleiner D, Drexler H, Heusch G, Schulz R. The myocardial JAK/STAT pathway: from protection to failure. Pharmacol Ther 2008; 120: 172-85.
2. Fischer P, Hilfiker-Kleiner D. Survival pathways in hypertrophy and heart failure: the gp130-STAT axis. Basic Res Cardiol 2007; 102: 393-411.
3. Heusch G, Musiolik J, Kottenberg E, Peters J, Jakob H, Thielmann M. STAT5 activation and cardioprotection by remote ischemic preconditioning in humans: short communication. Circ Res 2012; 110: 111-5.
4. Podewski EK, Hilfiker-Kleiner D, Hilfiker A, et al. Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy. Circulation 2003; 107: 798-802.
5. Kelly RF, Lamont KT, Somers S, et al. Ethanolamine is a novel STAT-3 dependent cardioprotective agent. Basic Res Cardiol 2010; 105: 763-70.
6. Boengler K, Buechert A, Heinen Y, et al. Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res 2008; 102: 131-5.
7. Heusch G, Musiolik J, Gedik N, Skyschally A. Mitochondrial STAT3 activation and cardioprotection by ischemic postconditioning in pigs with regional myocardial ischemia/reperfusion. Circ Res 2011; 109: 1302-8.
8. Bolli R, Stein AB, Guo Y, et al. A murine model of inducible, cardiac-specific deletion of STAT3: its use to determine the role of STAT3 in the upregulation of cardioprotective proteins by ischemic preconditioning. J Mol Cell Cardiol 2011; 50: 589-97.
9. Goodman MD, Koch SE, Fuller-Bicer GA, Butler KL. Regulating RISK: a role for JAK-STAT signaling in postconditioning? Am J Physiol Heart Circ Physiol 2008; 295: H1649-56.
10. Smith RM, Suleman N, Lacerda L, et al. Genetic depletion of cardiac myocyte STAT-3 abolishes classical preconditioning. Cardiovasc Res 2004; 63: 611-6.
11. Hattori R, Maulik N, Otani H, et al. Role of STAT3 in ischemic preconditioning. J Mol Cell Cardiol 2001; 33: 1929-36.
12. Xuan YT, Guo Y, Han H, Zhu Y, Bolli R. An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc Natl Acad Sci USA 2001; 98: 9050-5.
13. Lacerda L, Somers S, Opie LH, Lecour S. Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovasc Res 2009; 84: 201-8.
14. Gross ER, Hsu AK, Gross GJ. The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3 beta. Am J Physiol Heart Circ Physiol 2006; 291: H827-34.
15. Boengler K, Heusch G, Schulz R. Mitochondria in postconditioning. Antioxid Redox Signal 2011; 14: 863-80.
16. Di Lisa F, Carpi A, Giorgio V, Bernardi P. The mitochondrial permeability transition pore and cyclophilin D in cardioprotection. Biochim Biophys Acta 2011; 1813: 1316-22.
17. Gottlieb RA. Cell death pathways in acute ischemia/reperfusion injury. J Cardiovasc Pharmacol Ther 2011; 16: 233-8.
18. Crestanello JA, Doliba NM, Babsky AM, Niibori K, Osbakken MD, Whitman GJ. Mitochondrial function during ischemic preconditioning. Surgery 2002; 131: 172-8.
19. Murphy E, Steenbergen C. Preconditioning: the mitochondrial connection. Annu Rev Physiol 2007; 69: 51-67.
20. Penna C, Mancardi D, Rastaldo R, Pagliaro P. Cardioprotection: a radical view Free radicals in pre and postconditioning. Biochim Biophys Acta 2009; 1787: 781-93.
21. Zhou L, Too HP. Mitochondrial localized STAT3 is involved in NGF induced neurite outgrowth. PLoS One 2011; 6: e21680.
22. Wegrzyn J, Potla R, Chwae YJ, et al. Function of mitochondrial Stat3 in cellular respiration. Science 2009; 323: 793-7.
23. Boengler K, Hilfiker-Kleiner D, Heusch G, Schulz R. Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion. Basic Res Cardiol 2010; 105: 771-85.
24. Schust J, Sperl B, Hollis A, Mayer TU, Berg T. Stattic: a smallmolecule inhibitor of STAT3 activation and dimerization. Chem Biol 2006; 13: 1235-42.
25. Boengler K, Ruiz-Meana M, Gent S, et al. Mitochondrial connexin 43 impacts on respiratory complex I activity and mitochondrial oxygen consumption. J Cell Mol Med 2012; 16: 1649-55.
26. Suleman N, Somers S, Smith R, Opie LH, Lecour SC. Dual activation of STAT-3 and Akt is required during the trigger phase of ischaemic preconditioning. Cardiovasc Res 2008; 79: 127-33.
27. Lecour S. Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway? J Mol Cell Cardiol 2009; 47: 32-40.
28. Juhasz B, Varga B, Gesztelyi R, Kemeny-Beke A, Zsuga J, Tosaki A. Resveratrol: a multifunctional cytoprotective molecule. Curr Pharm Biotechnol, 2010; 11: 810-8.
29. Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs 2009; 18: 45-56.
30. Shulga N, Pastorino JG. GRIM-19 mediated translocation of STAT3 to mitochondria is necessary for TNF induced necroptosis. J Cell Sci 2012; 125: 2995-3003.
31. Fearnley IM, Carroll J, Shannon RJ, Runswick MJ, Walker JE, Hirst J. GRIM-19, a cell death regulatory gene product, is a subunit of bovine mitochondrial NADH: ubiquinone oxidoreductase (complex I). J Biol Chem 2001; 276: 38345-8.
32. Sarafian TA, Montes C, Imura T, et al. Disruption of astrocyte STAT3 signaling decreases mitochondrial function and increases oxidative stress in vitro. PLoS One 2010; 5: e9532.
33. Mantel C, Messina-Graham S, Moh A, et al. Mouse hematopoietic cell-targeted STAT3 deletion: stem/progenitor cell defects, mitochondrial dysfunction, ROS overproduction, and a rapid aginglike phenotype. Blood 2012; 120: 2589-99.
34. Zhou H, Newnum AB, Martin JR, et al. Osteoblast/osteocytespecific inactivation of Stat3 decreases load-driven bone formation and accumulates reactive oxygen species. Bone 2011; 49: 404-11.
35. Liu X, Guo W, Wu S, et al. Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells. Biochem Pharmacol 2012; 83: 1456-64.
36. Du W, Hong J, Wang YC, et al. Inhibition of JAK2/STAT3 signalling induces colorectal cancer cell apoptosis via mitochondrial pathway. J Cell Mol Med 2012; 16: 1878-88.
37. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin Dcleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007; 128: 589-600.
38. Obana M, Miyamoto K, Murasawa S, et al. Therapeutic administration of IL-11 exhibits the postconditioning effects against ischemia-reperfusion injury via STAT3 in the heart. Am J Physiol Heart Circ Physio, 2012; 303: H569-77.
39. Szczepanek K, Chen Q, Derecka M, et al. Mitochondrial-targeted Signal transducer and activator of transcription 3 (STAT3) protects against ischemia-induced changes in the electron transport chain and the generation of reactive oxygen species. J Biol Chem 2011; 286: 29610-20.
40. Sun X, Wu S, Xing D. The reactive oxygen species-Src-Stat3 pathway provokes negative feedback inhibition of apoptosis induced by high-fluence low-power laser irradiation. FEBS J 2010; 277: 4789-802.
41. Lei C, Deng J, Wang B, et al. Reactive oxygen species scavenger inhibits STAT3 activation after transient focal cerebral ischemiareperfusion injury in rats. Anesth Analg 2011; 113: 153-9.
42. Perrelli MG, Pagliaro P, Penna C. Ischemia/reperfusion injury and cardioprotective mechanisms: Role of mitochondria and reactive oxygen species. World J Cardiol 2011; 3: 186-200.
43. Di Lisa F, Canton M, Carpi A, et al. Mitochondrial injury and protection in ischemic pre-and postconditioning. Antioxid Redox Signal 2011; 14: 881-91.
44. Hausenloy DJ, Boston-Griffiths EA, Yellon DM. Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent. Br J Pharmacol 2012; 165: 1235-45.
45. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008; 359: 473-81.
46. Skyschally A, Schulz R, Heusch G. Cyclosporine A at reperfusion reduces infarct size in pigs. Cardiovasc Drugs Ther 2010; 24: 85-7.
47. Huang C, Gu H, Zhang W, Manukyan MC, Shou W, Wang M. SDF-1/CXCR4 mediates acute protection of cardiac function through myocardial STAT3 signaling following global ischemia/reperfusion injury. Am J Physiol Heart Circ Physiol 2011; 301: H1496-505.
48. Marin-Garcia J, Damle S, Jugdutt BI, Moe GW. Nuclearmitochondrial cross-talk in global myocardial ischemia. A timecourse analysis. Mol Cell Biochem 2012; 364: 225-34.
49. Szendrei L, Turoczi T, Kovacs P, Vecsernyes M, Das DK, Tosaki A. Mitochondrial gene expression and ventricular fibrillation in ischemic/reperfused nondiabetic and diabetic myocardium. Biochem Pharmacol 2002; 63: 543-52.
50. Lin KM, Lin B, Lian IY, Mestril R, Scheffler IE, Dillmann WH. Combined and individual mitochondrial HSP60 and HSP10 expression in cardiac myocytes protects mitochondrial function and prevents apoptotic cell deaths induced by simulated ischemiareoxygenation. Circulation 2001; 103: 1787-92.
51. Rowland RT, Meng X, Cleveland JC, Meldrum DR, Harken AH, Brown JM. Cardioadaptation induced by cyclic ischemic preconditioning is mediated by translational regulation of de novo protein synthesis. J Surg Res, 1997; 71: 155-60.
52. Matsuyama N, Leavens JE, McKinnon D, Gaudette GR, Aksehirli TO, Krukenkamp IB. Ischemic but not pharmacological preconditioning requires protein synthesis. Circulation 2000; 102: III312-8.
53. Bolli R. The late phase of preconditioning. Circ Res 2000; 87: 972-83.
54. West MB, Rokosh G, Obal D, et al. Cardiac myocyte-specific expression of inducible nitric oxide synthase protects against ischemia/reperfusion injury by preventing mitochondrial permeability transition. Circulation 2008; 118: 1970-8.
55. Boengler K, Schulz R, Heusch G. Loss of cardioprotection with ageing. Cardiovasc Res 2009; 83: 247-61.
56. Boengler K, Konietzka I, Buechert A, et al. Loss of ischemic preconditioning's cardioprotection in aged mouse hearts is associated with reduced gap junctional and mitochondrial levels of connexin 43. Am J Physiol Heart Circ Physiol 2007; 292: H1764-9.
57. Gross ER, Hsu AK, Gross GJ. Diabetes abolishes morphineinduced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3beta. Diabetes 2007; 56: 127-36.